ZFP57 Gene Maturity-Onset Diabetes of the Young (MODY) Sequencing Test in UAE | 2800 AED | DNA Labs UAE

Executive Summary & Core Metrics

Precision Monogenic Diabetes Diagnosis

This advanced sequencing test analyzes the entire coding region of the ZFP57 gene to identify pathogenic mutations responsible for Maturity-Onset Diabetes of the Young (MODY). With 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next-generation sequencing, this assay enables accurate reclassification of diabetes subtype and targeted therapeutic guidance. Results are delivered with a comprehensive telephonic clinical interpretation by a DHA-licensed genetics consultant.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS with Sanger Confirmation.
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
✓ Clinical Guidance: Telephonic Post-Test Interpretation by a Consultant Medical Genetics specialist.
✓ Price: 2800 AED | Turnaround Time: 3 to 4 Weeks | Sample Types: Whole Blood (EDTA), Extracted DNA, FTA Card.

Test Overview & Methodology

This genetic test performs comprehensive sequencing of the ZFP57 gene, a transcription factor essential for pancreatic beta-cell maturation and function. Pathogenic variants in ZFP57 cause a specific subtype of MODY, a monogenic form of diabetes frequently misclassified as Type 1 or Type 2 diabetes. Accurate molecular diagnosis enables precise therapeutic selection, often allowing transition from insulin to low-dose sulfonylurea therapy under appropriate clinical supervision.

The assay employs next-generation sequencing (NGS) covering all coding exons and splice junctions, with all clinically significant variants confirmed by Sanger sequencing to ensure 99.9% analytical accuracy. Results are correlated with established ACMG/AMP classification guidelines and interpreted in the context of the patient's clinical phenotype and family history.

Our Test vs. Closest Alternative

Feature	Our ISO-Certified NGS	Standard Panel/Exome
Target Precision	Full Gene Sequencing (ZFP57)	Hotspot/Limited Coverage
Methodology	NGS with Sanger Confirmation	NGS Only
Turnaround	3–4 Weeks Guaranteed	4–8+ Weeks

Physician Insight & Safety Protocols

A Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403):

"A ZFP57 sequencing result must be integrated with the patient's full glycemic history, family pedigree, and biomarker profile. A pathogenic variant confirms monogenic diabetes and may guide a carefully monitored transition from insulin to sulfonylurea therapy in select cases. However, a negative result does not exclude MODY, as mutations in HNF1A, HNF4A, GCK, and other genes must be considered based on the clinical presentation. Our telephonic genetic counseling bridges the gap between the raw molecular report and actionable diabetes management."

Medication Advisory

Do Not Alter Prescribed Therapy Without Physician Consultation

This genetic test result does not replace clinical judgment. Do not discontinue, reduce, or adjust insulin, sulfonylurea, or any other diabetes medication without direct consultation with your treating diabetologist or endocrinologist. Therapeutic decisions based on this report must be made exclusively by a qualified physician experienced in monogenic diabetes management.

Safety Exclusion Criteria & Emergency Red Flags

Do Not Proceed with Elective Genetic Testing If the Patient Presents With

Active diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) — Seek emergency care immediately.
Severe, persistent hypoglycemia unawareness or acute metabolic decompensation requiring urgent medical intervention.
Chest pain, altered mental status, or rapid breathing — proceed to the nearest Emergency Department immediately.

This is a non-acute, elective genetic test. It must not delay emergency management of acute metabolic crises.

Patient FAQ & Clinical Guidance

1. What does a positive ZFP57 mutation mean for my diabetes treatment plan?

A positive pathogenic ZFP57 mutation reclassifies your diabetes as monogenic MODY rather than Type 1 or Type 2 diabetes. This molecular diagnosis often enables a trial of low-dose oral sulfonylurea therapy under close medical supervision, potentially reducing or eliminating insulin requirements in responsive individuals. Your diabetologist will interpret the result alongside your C-peptide level, antibody profile, and glycemic history to determine the safest therapeutic approach.

2. Is this genetic test safe and approved for pediatric patients in the UAE?

Yes, this test is safe for minors and requires only a standard small-volume blood draw. In accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, written informed consent from a legal guardian is mandatory prior to sample collection for any patient under 18 years. Our phlebotomists are trained in pediatric collection and strictly verify consent documentation. Diagnosis of monogenic diabetes in children can prevent lifelong unnecessary insulin injections and improve long-term outcomes.

3. Are my genetic test results protected under UAE medical privacy laws?

Yes, your genomic data and identifiable health information are fully protected. DNA Labs UAE complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic data is processed with strict confidentiality, stored on encrypted servers, and never shared with third parties, employers, or insurers without your explicit opt-in consent.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework

DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of clinical governance and data protection. All testing protocols conform to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring patient genomic data is collected, processed, and stored with explicit consent and robust security controls. Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, and health information systems comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our laboratory maintains ISO 9001:2015 accreditation, reflecting a commitment to quality, accuracy, and patient safety in every stage of the testing pathway.

Clinical & Logistical Metadata

Test Name	ZFP57 Gene Maturity-Onset Diabetes of the Young (MODY) Sequencing
Price (AED)	2800
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood (EDTA), Extracted DNA, FTA Card
Methodology Used	Next-Generation Sequencing (NGS) with Sanger Confirmation
ICD-10-CM Code	E13.9
LOINC Code	94531-1
DHA Facility License & Laboratory Address	DHA Facility License: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE